TRAV30

Across TCGA pan-cancer cohorts, TRAV30 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAV30 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher TRAV30 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TRAV30 expression acts as an unfavorable survival marker.

CESC and SKCM are the cancer types where TRAV30 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.192	0.798	<.001	30	view →
SKCM	OS	Median	All	0.272	0.784	.001	17	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TRAV30–CESC (OS)

Open the CESC breakdown →